Myocardial Ischemia Market Research Report - Forecast till 2030

Myocardial Ischemia Market: Information by Type (Symptomatic and Asymptomatic), Treatment & Diagnosis (Diagnosis and Treatment), End User (Hospitals & Clinics, Diagnostic Centers and Ambulatory Surgery Centers) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2030

ID: MRFR/MED/4355-CR | 135 Pages | Published By Rahul Gotadki on August 2019         

Myocardial Ischemia Market Speak to Analyst Request a Free Sample

Myocardial Ischemia Market Overview

The Myocardial Ischemia Market is expected to reach USD 1186.12 Million by 2030 at 5.70% CAGR during the forecast period 2022-2030 Myocardial ischemia is a medical condition characterized by the insufficient blood flow to the heart muscle via coronary arteries, commonly resulting in chest pain.

Factors such as the high prevalence of coronary heart disease, rising incidence of diabetes, and lifestyle changes provide suitable backgrounds for the development of market growth. However, the high cost of therapeutic surgeries and side effects related to medications are projected to restrain the market growth during the forecast period.

Market Dynamics

Myocardial ischemia is a common occurrence and occurs with increased frequency in patients with diabetes due to cardiac autonomic dysfunction. According to a study published in the Endocrinology, Diabetes & Metabolism Case Reports journal in 2013, ~22% of the patients diagnosed with type 2 diabetes were estimated to suffer from Silent Myocardial Ischemia (SMI). Moreover, it is reported that the prevalence of diabetes has increased. This is illustrative by the fact sheet of the World Health Organization (WHO) published in 2017. According to it, the global prevalence of diabetes among individuals ages 18 years or more was about 8.5% in 2014. Thus, it is interpreted that the rising prevalence of diabetes provides a necessary driving force for the myocardial ischemia market to expand.

Myocardial Ischemia Market Size, by End User, 2017 (USD Million)  Myocardial Ischemia Market

 Source: MRFR Analysis


The myocardial ischemia market has been segmented into type, treatment & diagnosis, and end user. By type, the market has been bifurcated into symptomatic and asymptomatic. Based on treatment & diagnosis, the market has been divided into diagnosis and treatment. Diagnosis segment has been further segregated into imaging and stress test. The treatment has been further divided into medications and surgery. By end-user, the market has been classified as hospitals & clinics, diagnostic centers, ambulatory surgery centers, and others. The hospitals and clinics accounted for a market value of USD 18,744.2 million in 2023.

Key Players

The prominent players in the myocardial ischemia market are Taxus Cardium (US), ViroMed Co. Ltd. (Republic of Korea ), Edward Lifesciences (US), Daiichi Sankyo Company Limited (Japan), Boston Scientific Corporation (US), Merck KGaA (Germany), Novartis AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), Johnson & Johnson Services Inc. (US), Bayer AG (Germany), and AstraZeneca (UK).

Some of the key strategies followed by the players operating in the myocardial ischemia market were innovation, product development, acquisition, and expansion.

Asia-Pacific Myocardial Ischemia Market Share, by Country, 2017 (%) Myocardial Ischemia Market

Source: MRFR Analysis

Regional Analysis

The myocardial ischemia market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is estimated to dominate the myocardial ischemia market during the forecast period. Americas accounts for the largest regional market owing to the rising prevalence of diabetes, obesity, physical inactivity, and excessive alcohol use among the population. The European market for myocardial ischemia is expected to be the second-largest during the forecast period. The high growth rate is due to the high incidence rate of cardiovascular diseases in Europe. According to the European Cardiovascular Disease Statistics 2017, 45% of deaths in Europe is due to cardiovascular diseases (CVD).

Additionally, the companies operating in the market are mainly focusing on mergers and acquisition, which is expected to support market growth. Asia-Pacific is estimated to be the fastest-growing market due to the rising prevalence of diabetes. According to the Asian Diabetes Prevention Initiative, 60% of the world’s diabetic patient live in Asia. Such high incidences of diabetes that lead to silent myocardial ischemia are likely to fuel the market growth.

Moreover, in the Asia-Pacific region, China accounted for a market share of 23.5% in 2017. However, the Middle East and Africa are expected to observe slow growth due to less exposure to healthcare services and stringent government rules and regulations.

Key Updates

  • In July 2016, Angionetics Inc., a subsidiary of Taxus Cardium, entered into an agreement with Huapont Life Sciences covering a USD 3,000,000 investment, to support the Generx Phase 3 clinical and commercialization development program.

  • In February 2018Edwards Lifesciences Corporation received the CE Mark for its self-expanding CENTERA valve, thus enhancing its transcatheter heart valve therapy segment.

  • In August 2017, Boehringer Ingelheim Pharmaceuticals, Inc. received FDA approval for CyltezoTM (adalimumab-adbm).

Market Segmentation

Myocardial Ischemia Market, by Type

  • Symptomatic

  • Asymptomatic

Myocardial Ischemia Market, by Treatment & Diagnosis

  • Diagnosis

  • Treatment

Myocardial Ischemia Market, by End User

  • Hospitals & Clinics

  • Diagnostic Centres

  • Ambulatory Surgery Centres

Myocardial Ischemia Market, by Region

  • Americas

    • North America

      • US

      • Canada

    • Latin America

  • Europe

    • Western Europe

      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Rest of Western Europe

    • Eastern Europe

  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • Republic of Korea

    • Rest of Asia-Pacific

  • Middle East & Africa

    • United Arab Emirates

    • Saudi Arabia

    • Oman

    • Kuwait

    • Qatar

    • Rest of The Middle East & Africa

Available Additional Customizations

  • Regulatory scenario

Intended Audience

  • Medical device manufacturers and distributors

  • Government research organizations

  • Hospitals and clinics

  • Regulatory agencies

  • Pharmaceutical companies

Report Scope:

Report Attribute/Metric Details
  Market Size   2030: USD 1186.12 Million
  CAGR   5.70% (2022-2030)
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment & Diagnosis, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Taxus Cardium (US), ViroMed Co. Ltd. (Republic of Korea ), Edward Lifesciences (US), Daiichi Sankyo Company Limited (Japan), Boston Scientific Corporation (US), Merck KGaA (Germany), Novartis AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), Johnson & Johnson Services Inc. (US), Bayer AG (Germany), and AstraZeneca (UK).
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Rising prevalence of diabetes
  • The increasing cases of coronary artery disease and diabetes
  • Growing awareness related to heart conditions
  • Technological advancement in treatments
  • Rising numbers of hospitals and healthcare infrastructure

  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Myocardial ischemia market projected to grow at approximately 5.70% CAGR during the assessment period (2022-2030).

    The valuation of the myocardial ischemia market is estimated to increase to USD 50,120.3 MN by the end of 2023.

    Increasing awareness about heart conditions, technological advancement in medical science, and rising numbers of hospitals & healthcare infrastructure, are major tailwinds pushing the growth of the global myocardial ischemia market.

    North America holds the largest share in the myocardial ischemia market, followed by Europe and the Asia Pacific, respectively.

    ViroMed Co. Ltd. (Korea), Johnson & Johnson Services Inc. (US), Boehringer Ingelheim International GmbH (Germany), Taxus Cardium (US), Bayer AG (Germany), Daiichi Sankyo Company Limited (Japan), AstraZeneca (UK), Edward Lifesciences (US), Boston Scientific Corporation (US), Novartis AG (Switzerland), and Merck KGaA (Germany), are some of the top players operating in the myocardial ischemia market.